Inovio Pharmaceuticals, Inc.
Here’s whether Inovio Pharmaceuticals, Inc. (INO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.60% over 10 days); RSI 21 — oversold; weak 1-year return of -35.8%; 3-month momentum negative (-15.6%). Currently 67.4% off its 52-week high. Score: -7/7.
INO is trading below its 200-day MA ($1.62) — a key warning sign the longer-term trend is under pressure. An RSI of 21.2 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -35.8% compares to +16.5% for SPY (trailed the market by 52.2%). The current 67.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.